In a conference season dominated by mega-cap immunology franchises, Eupraxia Pharmaceuticals (NASDAQ: EPRX) quietly walked into AAAAI 2026 and walked out looking a lot less “micro‑cap” and a lot more “mispriced asset.” For investors willing to do more than skim the abstracts,…
